January 17th 2025
Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Wuxi's Biologics Facility Receives Honorable Mention at ISPE Facility of the Year Awards 2014
October 20th 2014The WuXi AppTec bulk cell culture production facility, designed by Sartorius Stedim Biotech (SSB), received an honorable mention in the 2014 Facility of the Year Awards at the annual meeting of International Society for Pharmaceutical Engineering (ISPE) in Las Vegas last week.